BDL-SP: A Bio-inspired DL model for the identification of altered Signaling Pathways in Multiple Myeloma using WES data.
AI in cancer
MGUS
ShAP
genomic aberrations
haematological malignancy
multiple myeloma
Journal
American journal of cancer research
ISSN: 2156-6976
Titre abrégé: Am J Cancer Res
Pays: United States
ID NLM: 101549944
Informations de publication
Date de publication:
2023
2023
Historique:
received:
02
12
2022
accepted:
23
03
2023
medline:
12
5
2023
pubmed:
12
5
2023
entrez:
11
5
2023
Statut:
epublish
Résumé
Identification of the genomic features responsible for the progression of Multiple Myeloma (MM) cancer from its precancerous stage MGUS can improve the understanding of the disease pathogenesis and, in devising suitable preventive and treatment measures. We have designed an innovative AI-based model, namely, the Bio-inspired Deep Learning architecture for the identification of altered Signaling Pathways (BDL-SP) to discover pivotal genomic biomarkers that can potentially distinguish MM from MGUS. The proposed BDL-SP model comprehends gene-gene interactions using the PPI network and analyzes genomic features using a deep learning (DL) architecture to identify significantly altered genes and signaling pathways in MM and MGUS. For this, whole exome sequencing data of 1174 MM and 61 MGUS patients were analyzed. In the quantitative benchmarking with the other popular machine learning models, BDL-SP performed almost similar to the two other best performing predictive ML models of Random Forest and CatBoost. However, an extensive post-hoc explainability analysis, capturing the application specific nuances, clearly established the significance of the BDL-SP model. This analysis revealed that BDL-SP identified a maximum number of previously reported oncogenes, tumor-suppressor genes, and actionable genes of high relevance in MM as the top significantly altered genes. Further, the post-hoc analysis revealed a significant contribution of the total number of single nucleotide variants (SNVs) and genomic features associated with synonymous SNVs in disease stage classification. Finally, the pathway enrichment analysis of the top significantly altered genes showed that many cancer pathways are selectively and significantly dysregulated in MM compared to its precursor stage of MGUS, while a few that lost their significance with disease progression from MGUS to MM were actually related to the other disease types. These observations may pave the way for appropriate therapeutic interventions to halt the progression to overt MM in the future.
Types de publication
Journal Article
Langues
eng
Pagination
1155-1187Informations de copyright
AJCR Copyright © 2023.
Déclaration de conflit d'intérêts
None.
Références
Bioinformatics. 2012 Feb 1;28(3):311-7
pubmed: 22155872
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
Am J Cancer Res. 2022 Apr 15;12(4):1919-1933
pubmed: 35530275
BMC Cancer. 2019 Apr 16;19(1):359
pubmed: 30991970
Nucleic Acids Res. 2020 Feb 20;48(3):1192-1205
pubmed: 31950163
Quant Biol. 2020 Dec 24;8(4):347-358
pubmed: 34336363
Genome Biol. 2016 Aug 24;17(1):178
pubmed: 27557938
PLoS Comput Biol. 2019 Sep 30;15(9):e1007381
pubmed: 31568528
Nat Commun. 2014;5:2997
pubmed: 24429703
Leukemia. 2014 Feb;28(2):384-390
pubmed: 23817176
Transl Oncol. 2021 Sep;14(9):101157
pubmed: 34247136
Front Oncol. 2021 Nov 09;11:720932
pubmed: 34858811
Cell. 2017 Nov 16;171(5):1029-1041.e21
pubmed: 29056346
BMC Bioinformatics. 2021 Oct 25;22(Suppl 4):491
pubmed: 34689757
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Front Genet. 2021 Aug 16;12:700874
pubmed: 34484298
Haematologica. 2017 Sep;102(9):1617-1625
pubmed: 28550183
Blood. 2018 Aug 9;132(6):587-597
pubmed: 29884741
Hum Mutat. 2017 Apr;38(4):339-342
pubmed: 28026089
Leukemia. 2019 Feb;33(2):457-468
pubmed: 30046162
Blood Cancer J. 2018 Mar 21;8(3):35
pubmed: 29563506
Meta Gene. 2014 Oct 09;2:730-6
pubmed: 25606456
BMC Bioinformatics. 2013 Apr 15;14:128
pubmed: 23586463
Nat Rev Genet. 2011 Jan;12(1):56-68
pubmed: 21164525
J Immunother Cancer. 2021 Jul;9(7):
pubmed: 34272304
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28890946
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Leukemia. 2020 Jan;34(1):322-326
pubmed: 31439946
Nat Commun. 2019 Aug 23;10(1):3835
pubmed: 31444325
Sci Rep. 2017 Nov 21;7(1):15959
pubmed: 29162841
Leukemia. 2021 Oct;35(10):2924-2935
pubmed: 34007046
G3 (Bethesda). 2019 Nov 5;9(11):3575-3582
pubmed: 31455677
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
J Immunol. 2018 Apr 15;200(8):2581-2591
pubmed: 29531171
Int J Hematol. 2022 Jun;115(6):799-810
pubmed: 35583724
Front Immunol. 2018 Dec 04;9:2848
pubmed: 30564241
Eur J Haematol. 2016 Dec;97(6):568-575
pubmed: 27157252
Curr Protoc. 2021 Mar;1(3):e90
pubmed: 33780170
Ann Hematol. 2018 Dec;97(12):2447-2454
pubmed: 30056581
Transl Oncol. 2022 Jun 28;23:101472
pubmed: 35777247
Leukemia. 2016 Nov;30(11):2260-2264
pubmed: 27461064
Cell Cycle. 2016;15(1):25-40
pubmed: 26636629
Blood. 2022 Feb 24;139(8):1160-1176
pubmed: 35201323
Leukemia. 2012 Dec;26(12):2521-9
pubmed: 22565645
Cell. 2014 Mar 13;156(6):1324-1335
pubmed: 24630730
Nat Genet. 2015 Jul;47(7):692-5
pubmed: 26111507
Cytokine. 2020 Dec;136:155271
pubmed: 32916474
Cancer Cell. 2014 Jan 13;25(1):91-101
pubmed: 24434212
J Clin Oncol. 2020 Nov 20;38(33):3895-3904
pubmed: 32758030
Bioinformatics. 2018 Feb 1;34(3):511-513
pubmed: 28968714
Nucleic Acids Res. 2021 Jan 8;49(D1):D605-D612
pubmed: 33237311
Nature. 2011 Mar 24;471(7339):467-72
pubmed: 21430775
Cancer Treat Res. 2016;169:23-34
pubmed: 27696256
J Clin Oncol. 2015 Nov 20;33(33):3911-20
pubmed: 26282654
Nat Commun. 2019 Jun 12;10(1):2569
pubmed: 31189880
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
Genome Res. 2019 Jul;29(7):1134-1143
pubmed: 31171634
Nat Rev Cancer. 2020 Oct;20(10):555-572
pubmed: 32778778
Curr Protoc Bioinformatics. 2013;43:11.10.1-11.10.33
pubmed: 25431634
Nucleic Acids Res. 2019 May 7;47(8):e45
pubmed: 30773592
PLoS One. 2020 Sep 2;15(9):e0232644
pubmed: 32877430
BMC Med Genomics. 2019 May 16;12(1):63
pubmed: 31096972
Genome Res. 2012 Mar;22(3):568-76
pubmed: 22300766
PLoS One. 2021 Jul 28;16(7):e0254596
pubmed: 34320000
Am J Cancer Res. 2021 Nov 15;11(11):5659-5679
pubmed: 34873486
Front Genet. 2019 Jan 29;10:13
pubmed: 30761181
Front Oncol. 2020 Jan 08;9:1442
pubmed: 31970084
Proc Natl Acad Sci U S A. 2007 May 22;104(21):8685-90
pubmed: 17502601